Genetic Obesity and Bariatric Surgery Outcome in 1014 Patients with Morbid Obesity.
Mellody I CooimanL KleinendorstE O AartsI M C JanssenH K Ploos van AmstelA I BlakemoreE J HazebroekH J Meijers-HeijboerB van der ZwaagF J BerendsM M van HaelstPublished in: Obesity surgery (2021)
In this cohort of morbid obese bariatric patients, an estimated prevalence of monogenic obesity of 3% is reported. Among these patients, the clinical effects of heterozygous mutations in POMC and PCSK1 do not interfere with the effectiveness of most commonly performed bariatric procedures within the first 2 years of follow-up. Patients with MC4R mutations achieved superior weight loss after primary RYGB compared with SG.
Keyphrases
- weight loss
- bariatric surgery
- roux en y gastric bypass
- obese patients
- end stage renal disease
- gastric bypass
- metabolic syndrome
- ejection fraction
- newly diagnosed
- type diabetes
- chronic kidney disease
- insulin resistance
- peritoneal dialysis
- prognostic factors
- glycemic control
- weight gain
- high fat diet induced
- gene expression
- patient reported outcomes
- early onset
- adipose tissue